ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) COO Muthusamy Shanmugam sold 16,809 shares of ANI Pharmaceuticals stock in a transaction on Friday, April 19th. The shares were sold at an average price of $65.17, for a total value of $1,095,442.53. Following the sale, the chief operating officer now directly owns 782,620 shares of the company's stock, valued at $51,003,345.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Muthusamy Shanmugam also recently made the following trade(s):
- On Wednesday, April 17th, Muthusamy Shanmugam sold 9,520 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.40, for a total transaction of $622,608.00.
- On Monday, April 15th, Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $66.33, for a total transaction of $491,770.62.
- On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $66.35, for a total transaction of $1,000,889.75.
- On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $65.35, for a total value of $659,577.55.
ANI Pharmaceuticals Stock Performance
ANIP opened at $65.62 on Tuesday. The company has a market cap of $1.38 billion, a P/E ratio of 78.12 and a beta of 0.79. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The firm's 50-day moving average price is $65.12 and its 200-day moving average price is $58.70. ANI Pharmaceuticals, Inc. has a 52-week low of $36.99 and a 52-week high of $70.81.
Global crypto currency reset (41 major banks signed up)
From Stansberry Research | Ad
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Here's everything you need to know.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. The company had revenue of $131.65 million for the quarter, compared to the consensus estimate of $123.02 million. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current fiscal year.
Hedge Funds Weigh In On ANI Pharmaceuticals
Several hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its position in ANI Pharmaceuticals by 287.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company's stock worth $1,471,000 after acquiring an additional 15,790 shares during the period. BTC Capital Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the first quarter worth about $580,000. Los Angeles Capital Management LLC boosted its position in ANI Pharmaceuticals by 27.6% in the first quarter. Los Angeles Capital Management LLC now owns 24,974 shares of the specialty pharmaceutical company's stock valued at $1,726,000 after buying an additional 5,408 shares during the last quarter. Clear Street Markets LLC acquired a new position in ANI Pharmaceuticals in the 4th quarter worth approximately $140,000. Finally, Comerica Bank raised its position in ANI Pharmaceuticals by 4.6% during the 4th quarter. Comerica Bank now owns 36,855 shares of the specialty pharmaceutical company's stock worth $2,032,000 after buying an additional 1,626 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on ANIP shares. Truist Financial raised their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a "buy" rating in a research report on Friday, March 1st. HC Wainwright raised their price target on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a "buy" rating in a report on Monday, March 4th. Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a "buy" rating in a research note on Tuesday, March 5th. Finally, Capital One Financial assumed coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an "overweight" rating and a $80.00 target price for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat, ANI Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $80.00.
View Our Latest Analysis on ANIP
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
